Doctors: Cuba’s Coronavirus Miracle Cure ‘Harmful to

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
209
Doctors: Cuba’s Coronavirus Miracle Cure
‘Harmful to the Lives of Thousands Worldwide’
< >

GettyImages-1206754199-200x150.png

The human rights NGO Cuban Prisoners Defenders published an article on Friday citing three Cuban medical researchers who concluded that the communist regime’s publicity campaign for Interferon alpha-2b, which it claims can cure Chinese coronavirus, is a “serious crime against world public health.”

“When the Government of Cuba assures that the Interferon developed in Cuba cures the coronavirus, it is committing a serious crime against world public health, since this drug not only lacks any scientific proof, but also where it has been tested has already given null results of encouragement,” the doctors concluded, urging the World Health Organization (W.H.O.) to formally condemn the Cuban Communist Party for urging off-label use of a dangerous drug when no clinical trials or scientific confirmations exist that it works.

Interferons are “involved in alerting the cellular immune system to viral infection of host cells. Interferons not only exhibit important antiviral effects but also exert a key influence on the quality of the cellular immune responses and amplify antigen presentation to specific T cells.” A study published in 2004 in the Journal of Clinical Virology found that interferon-beta can “strongly” block multiplication of the Sudden Acute Respiratory Syndrome (SARS) virus, a type of coronavirus, in human cells, but that interferon-alpha and interferon-gamma did not appear to have the same effect.

The Wuhan coronavirus is believed to be closely related to the SARS coronavirus. Cuba has spent months promoting a domestically developed interferon – interferon-alpha 2b – as a successful antiviral against the Wuhan virus, offering little to no evidence.

The doctors writing the Cuban Prisoners Defenders article warn that the use of interferon-alpha can cause severe side effects in patients while potentially having no effect on the Chinese coronavirus.

“Eminent Cuban doctors who have helped to prepare this report have witnessed its use in the elderly hospitalized with severe, community and hospital pneumonia – now classified as associated with health care – and have attested to Prisoners Defenders of the null reduction in mortality,” the report reads. “The existence of the corresponding clinical trials that justify their use is also unknown.”

The doctors note that the Cuban Communist Party’s argument in favor of the drug is simply that many who have taken it have also survived a Chinese coronavirus infection, which they conclude is insufficient evidence for global use of a drug with severe side effects.

If we consider that most patients develop mild or uncomplicated forms of the disease – some without symptoms – around approx. 14% can present severe forms with the need to receive oxygen, and another approx. 5% may require admission to Intensive Care units, how is it possible to ensure that the good evolution of most patients is due to the use of Heberferon [the brand name for Cuban interferon-alpha 2b] and not to the natural course of the disease?

If there are no minimally serious scientific protocols, with a control group, that is, patients who do not receive this drug to compare the evolution with those who do, and even other placebo control groups, the results are more than questionable and are not minimally serious.

It does not have the minimum necessary to be considered a scientific investigation.

As interferon-alpha has been used to treat hepatitis, the report quotes a hepatologist, Edward Mena, who states that their use results in a “very strong and difficult treatment.”

“The side effects are like you’re in chemical therapy. Patients have nausea, vomiting, body pain, anemia; platelets, white blood cells are lowered … it is a very strong and difficult treatment. The side effects are many,” Mena reportedly said.

The drug could “kill, rather than cure patients,” the doctors say.

Granma, the official publication of the Cuban Communist Party, proclaimed in March that the Cuban interferon was showing “effectiveness in treating patients with the new SARS Cov-2 coronavirus.” It thanked Fidel Castro – a lawyer, not a virologist, by trade – for the “visionary thinking” that created the interferon and claimed that Cuban and Chinese scientists came up with the treatment together. Granma had previously stated that Cuba was somehow developing 22 drugs to fight coronavirus, none of them accepted as treatments for the Wuhan virus.

Interferon-alpha 2b’s use against coronavirus in Wuhan, where the virus originated, has become part of the Cuban state media lore about its success. Yet the doctors writing for Cuban Prisoners Defenders say “experts [in Wuhan] come to tell us to ‘try if you want, but we have tried it and we have not obtained evidence of its benefits.'”

Cuban Prisoners Defenders concludes that the “reckless and dangerous” use and promotion of the drug is an attempt by the Cuban government to enrich itself even further off of its medical businesses, the largest of which is its $11-billion-a-year slave doctor trade.

“Cuba generates from 2 to 6 times the national income of tourism through the “rent” in a state of slavery of doctors that are sent to more than 60 countries in the world,” the doctors write.

While no drug has received universal approval as a safe treatment for coronavirus, the use of interferon-beta – not the interferon Cuba is promoting – is part of a drug cocktail undergoing trials under the W.H.O.’s auspices. Testing has reportedly begun on the use of interferon-beta along with two antivirals, Science magazine reported in March. One of the researchers the magazine quoted warned, “if it is given late in the disease it could easily lead to worse tissue damage instead of helping patients.”

Cuba has documented 923 cases of Chinese coronavirus as of Friday; 31 people have died, according to the communist government.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Impresses with High Honors in Florida

Updated Category News Views 149

Legal Powerhouse Garners Accolades You know it's a big deal when a law firm like Greenberg Traurig gets the spotlight at the Florida Legal Luminaries Gala. Held on October 29 in the scenic Key Biscayne, this event was all about recognizing who’s who in the high-stakes world of law. Greenberg Traurig walked away with the 'Best Large Law Firm' award, cementing its stature...

Continue Reading
Stoneleigh Celebrates Forbes VERIFIED Luxury Praise

Updated Category News Views 128

Stoneleigh's Milestone in Luxury Living There are times when a luxury residence transcends mere bricks and mortar, and lands squarely in the realm of a lavish lifestyle. That's exactly what Residences at the Stoneleigh in Dallas aims to provide. Recently, the property snagged the coveted VERIFIED™ Luxury Residences designation from Forbes Travel Guide. Now, whether...

Continue Reading
Research Solutions Set to Reveal Q1 FY27 Results

Updated Category News Views 89

Understanding the Stakes Ahead of RSSS's Earnings Call Aw, the sweet suspense of earnings season. Research Solutions, Inc. (NASDAQ: RSSS) has circled November 12, 2026, as the date to let investors in on its numbers for the first quarter of fiscal year 2027. A date that's gotta have the folks over at RSSS feeling like it’s judgment day. You know how it goes—market...

Continue Reading
Ameren Ups Earnings Guidance Amid Strong Q3 2026

Updated Category News Views 125

A Boost in Earnings During a Hot Third Quarter Ameren Corporation, ticker NYSE: AEE, just released its third quarter 2026 results, and things are looking brighter on the earnings front. We're seeing a bump here, with GAAP diluted EPS hitting $2.42 compared to the $2.35 from the year before. Adjusted EPS follows suit, jumping from $2.17 in 2025 to that same $2.42 mark now....

Continue Reading
Tetragon Declares Dividend Amidst Regulation Challenges

Updated Category News Views 43

What Keeps Investors on Their Toes Tetragon Financial Group is ringing the dividend bell again—a solid 12 cents a share coming your way. But don't just kick your feet up and watch the cash roll in; there's a tangle of juicy tidbits and regulatory strings attached that make this more than your run-of-the-mill payout announcement. A Look at the Dividend Breakdown For...

Continue Reading
MAURE Injects Fresh Style into Holiday Gatherings

Updated Category News Views 102

Setting the Holiday Mood, MAURE Style Ever feel like your holiday gatherings need a little extra flair? Enter MAURE and their 2026 holiday collection, promising to make your seasonal get-togethers anything but ordinary. This is all about bringing some fresh style to your celebrations. They've got decorative Swedish birchwood trays that scream elegance, and their signature...

Continue Reading
Hyster-Yale Navigates a Rocky Q3 2026 Recovery

Updated Category News Views 60

Imagine Hyster-Yale like a battered ship in a stormy market, steering its way towards stability with a few promising signals on the horizon. Despite a 15% dip in revenue compared to last year, they're celebrating a hefty boost in bookings—up 45% from the rough waters of Q2 2025. It's a mixed bag of tales from the latest quarterly results that might have you scratching...

Continue Reading
Silversea Opens World's Southernmost Hotel in Chile

Updated Category News Views 0

Launching into the Frozen Frontier Roll out the red carpet—or should I say, the white one—because Silversea's just dropped a hospitality bombshell down at the ends of the Earth. The Cormorant at 55 South flung its doors wide open, setting Puerto Williams, Chile, in the limelight. And boy, it's making waves. We're talking about the southernmost hotel on this spinning...

Continue Reading
UP Fintech Faces 25% Stock Drop Amid Fraud Suit

Updated Category News Views 78

Stock Market Whiplash: UP Fintech's Rough Ride You know, just when you think you've seen it all in this bonkers stock market world, something like a 25% drop in UP Fintech’s stock reminds you that surprises never end. Now, UP Fintech’s facing a class action lawsuit, alleging it didn’t exactly play fair, sparking this latest rollercoaster ride. Yeah, buckle up folks,...

Continue Reading
Upright Proton Therapy: New Era for Cancer Care

Updated Category News Views 147

BayCare's Bold Step into Upright Proton Therapy Here's a twist for you—BayCare Health System has rolled out something that's genuinely pushing the envelope in cancer treatment. They've treated their first patient with an upright proton therapy system. Now, talk about innovation that shakes things up. This isn't just any old upgrade; it's a complete revamp of how proton...

Continue Reading

Top 5 Most Recently Viewed Articles

Tyler Technologies Upgrades EEO Management Software for Clients

Updated Category News Views 204

Tyler Technologies, Inc. (NYSE: TYL) grabbed attention back in 2024 with its shift from the outdated ICOMPLAINTS system to a more advanced EEO (Equal Employment Opportunity) Case Management software. This was more than just an update; it was a clear signal of Tyler’s strategy to equip federal agencies with state-of-the-art tools for navigating the complexities of EEO...

Continue Reading
Supporting Senior Veterans: Wreaths Across America Initiatives

Updated Category News Views 49

Supporting Senior Veterans Through Dedicated Initiatives Wreaths Across America Radio is thrilled to announce an important round table event that tackles the challenges senior veterans face. This program will highlight the vital work of two respected nonprofits, Hero's Bridge and Veteran's Last Patrol, which are dedicated to enhancing the quality of life for aging...

Continue Reading
ASE Technology Enhances Semiconductor Production in Malaysia

Updated Category News Views 611

ASE Technology's Strategic Expansion in Malaysia ASE Technology Holding Co., Ltd. is witnessing a boost in its shares as the company unveils plans for its fifth manufacturing plant in Penang. This new facility significantly enhances its packaging and testing capabilities, further reinforcing its commitment to the semiconductor industry. Growth and Expansion Plans This...

Continue Reading
Introducing the VFX SwitchBlade Wallet: A Game Changer for Bitcoin

Updated Category News Views 318

Understanding the VFX SwitchBlade Wallet The VerifiedX Network has recently launched the VFX SwitchBlade, a game-changing non-custodial wallet designed for Bitcoin enthusiasts. This innovative wallet offers full native Bitcoin functionality and adds an essential layer of security and decentralization. By integrating Verified Bitcoin (vBTC), users can enjoy enhanced...

Continue Reading
UPCX Wallet Innovates with New Features and Testnet Access

Updated Category News Views 129

UPCX Wallet Unveils Exciting Features and Opens Testnet Recently, UPCX, a prominent player in the open-source payment landscape, made headlines with the launch of innovative features for its Web3 wallet and an invitation to the public to explore its testnet. This initiative allows users to immerse themselves in the vast potential of digital payments, driving UPCX's...

Continue Reading